Effect of High Altitude
Conditions
Brief summary
prospective controlled interventional trial evaluating the efficacy of a 3-weeks asthma rehabilitation program at high altitude (3200m) and low altitude (760m) on lung function and asthma control.
Detailed description
Low altitude baseline measurements will be performed in Bishkek. Participants will then either be assigned to a rehabilitation program in Bishkek (760m) or in Tuja Ashu (3200m). The rehabilitation programs in high or low altitude will be identically performed and will comprise * asthma education and awareness * instruction on inhaled therapies * smoking cessation counseling * respiratory and skeletal muscle training in groups * guided walks / cycle ergometer training * questionnaires on asthma control, quality of life * spirometry and peak flow measurements * echocardiography Measurement on study subjects will be performed at baseline (Bishkek), during the rehabilitation program, after completion of the rehabilitation program and during a follow-up at week 15.
Interventions
OTHERaltitude rehabilitation program
altitude exposure
OTHERrehabilitation program
Rehabilitation at low altitude
Sponsors
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
University of Zurich
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* diagnosed with atopic or non-atopic Asthma for at least 3 months * partly controlled on regular or on demand inhaled therapy according to guidelines. * asthma variability in peak expiratory flow \> 10%/day and/or a reversible airflow obstruction in spirometry * History of asthma consisting of variable symptoms (cough, dyspnea, wheezing).
Exclusion criteria
* Unstable and severely uncontrolled asthma needing systemic corticosteroids. * Need of continuous oral steroids for their asthma control * Heavy smokers (\>20 cigarettes per day) * Severe concomitant diseases preventing patients to adhere to the protocol and/or altitude exposure (severe metabolic, kidney- or liver disease, heart failure (ejection fracture \<50%). * Chronic lung diseases with a persistent FVC \< 60% an/or arterial oxygen saturation \<92%). * Severe mental- or musculoskeletal disorders * Pregnant or breast feeding women * Patient which are unable to comply with the study procedure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| daily peak-flow variability | assessed at baseline, at run time of the rehabilitation program and 15 weeks after baseline measurements |
| change in asthma control questionnaire score | baseline to week 3 and 15 |
Secondary
| Measure | Time frame |
|---|---|
| spirometric values (Forced vital capacity (FVC), FEV1/FVC) | from baseline to week 3 and 15 |
| asthma-related quality of life (AQLQ) | from baseline to week 3 and 15 |
| generic quality of life (Short-Form 36(SF-36)) | from baseline to week 3 and 15 |
| symptoms of acute mountain sickness (AMS) by the environmental symptom cerebral score (AMS-c) | from baseline to week 3 and 15 |
| forced expiratory volume in 1 second (FEV1) | baseline to week 3 and 15 |
| sit-to-stand test | from baseline to week 3 and 15 |
| arterial oxygen saturation by pulse oximetry | from baseline to week 3 and 15 |
| visual analog scale (VAS) | from baseline to week 3 and 15 |
| 6 minute walk distance | from baseline to week 3 and 15 |
| average peak flow over 2 days | baseline to week 3 and 15 |
Countries
Switzerland
Outcome results
None listed